1. Home
  2. DXLG vs CRVO Comparison

DXLG vs CRVO Comparison

Compare DXLG & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

N/A

Current Price

$0.41

Market Cap

24.5M

ML Signal

N/A

Logo CervoMed Inc.

CRVO

CervoMed Inc.

N/A

Current Price

$1.79

Market Cap

21.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DXLG
CRVO
Founded
1976
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5M
21.5M
IPO Year
1994
2011

Fundamental Metrics

Financial Performance
Metric
DXLG
CRVO
Price
$0.41
$1.79
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$1.13
★ $14.80
AVG Volume (30 Days)
66.4K
★ 297.7K
Earning Date
12-03-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $435,017,000.00
$4,006,510.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.48
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.36
$1.27
52 Week High
$1.58
$10.00

Technical Indicators

Market Signals
Indicator
DXLG
CRVO
Relative Strength Index (RSI) 40.20 43.19
Support Level $0.40 N/A
Resistance Level $0.55 $4.27
Average True Range (ATR) 0.05 0.22
MACD -0.00 -0.02
Stochastic Oscillator 8.08 49.84

Price Performance

Historical Comparison
DXLG
CRVO

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.

About CRVO CervoMed Inc.

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Share on Social Networks: